论文部分内容阅读
目的：探讨乳腺良、恶性病变与ＰＣＮＡ、ｐ５３ 之间的关系及其在临床中的应用价值。方法：６０ 例乳腺癌原发灶，１６ 例乳腺增殖症及９ 例乳腺癌旁异型小叶蜡块采用ＬＳＡＢ 法标记ＰＣＮＡ、ｐ５３ 。结果：ＰＣＮＡ、ｐ５３ 阳性率在三种病变中有非常显著性差异。当ＰＣＮＡ 表达强度为（ ＋ ＋ ～＋ ＋ ＋ ） 时，其阳性率与乳腺癌病理分级、淋巴结有否转移及转移数目呈正相关。ｐ５３ 的表达与组织分化、淋巴结转移情况无明显关系。结论：ＰＣＮＡ 是瘤细胞增生活跃的指标，是判断乳腺癌预后的有效标记物。ｐ５３ 蛋白表达是乳腺癌发生的始动因素之一， 是判断乳腺良、恶性病变的参考指标，但不适合作为乳腺癌理想的预后标记物。
Objective: To investigate the relationship between benign and malignant breast lesions, PCNA and p53 and their clinical value. Methods: 60 cases of primary breast cancer, 16 cases of breast hyperplasia and 9 paraneoplastic paraffin wax blocks were labeled with PCNA and p53 by LSAB method. Results: The positive rates of PCNA and p53 were highly significant in the three lesions. When the expression intensity of PCNA was (+ + ~ + + + ), the positive rate was positively correlated with pathological grade, lymph node metastasis and metastasis number of breast cancer. The expression of p53 was not significantly related to histological differentiation or lymph node metastasis. Conclusion: PCNA is an indicator of hyperplasia of tumor cells and is a useful marker for predicting the prognosis of breast cancer. P53 protein expression is one of the initiating factors of breast cancer development and is a reference index for judging breast benign and malignant lesions, but it is not suitable as an ideal prognostic marker for breast cancer.